about
Diagnosis and management of goutThe dynamics of chronic gout treatment: medication gaps and return to therapyValidity versus feasibility for quality of care indicators: expert panel results from the MI-Plus study.Febuxostat: the evidence for its use in the treatment of hyperuricemia and goutA national survey of Veterans Affairs rheumatologists for relevance of quality of care indicators for gout management.Can racial disparities in optimal gout treatment be reduced? Evidence from a randomized trialMethods of formal consensus in classification/diagnostic criteria and guideline development.Patients and providers view gout differently: a qualitative study.Gout, urate-lowering therapy, and uric acid levels among adults in the United StatesSex differences in gout epidemiology: evaluation and treatment.Impact of deficits in gout care on hospitalizations.The prescription of allopurinol in a tertiary care centre: appropriate indications and dose adjustmentEmerging Role of Quality Indicators in Physical Therapist Practice and Health Service DeliveryAdvances in the management of gout and hyperuricaemia.Quality of care for gout in the US needs improvement.2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.Why is gout so poorly managed?Primary care providers' knowledge, beliefs and treatment practices for gout: results of a physician questionnaireKnowledge, illness perceptions and stated clinical practice behaviour in management of gout: a mixed methods study in general practiceAdherence with urate-lowering therapies for the treatment of gout.A quality indicator set for systemic lupus erythematosus.Quality of life and quality of care for patients with gout.Quality indicator set for systemic sclerosis.Utility of the Morisky Medication Adherence Scale in gout: a prospective study.Trends in physician diagnosed gout and gout therapies in the US: results from the national ambulatory health care surveys 1993 to 2009.Systematic review of the literature informing the systemic lupus erythematosus indicators project: reproductive health care quality indicators.The challenges of gout management in the elderly.Febuxostat treatment for gout: what the clinician needs to know.Quality indicators for inflammatory bowel disease: development of process and outcome measures.Drug discovery for hyperuricemia.Chinese herbal medicine for gout: a systematic review of randomized clinical trials.Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.Rheumatologists' perception of systemic lupus erythematosus quality indicators: significant interest and perceived barriers.Neutropenia in the Elderly: A Rheumatology Perspective.Evaluation of quality indicators and disease damage in childhood-onset systemic lupus erythematosus patients.Management of gout in the real world: current practice versus guideline recommendations.Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD).Adherence with urate-lowering therapies among male patients with gout in a routine clinical setting.Measuring physician adherence with gout quality indicators: a role for natural language processing.Rates of adherence and persistence with allopurinol therapy among gout patients in Israel.
P2860
Q24546235-EBAD8FFB-2AB0-4E90-93D9-3BA697C82A55Q33617747-59385F74-EB6D-4FAF-909B-CF0483EC0A99Q33845770-6E01E63E-ED6F-4260-A50A-08783837F1A9Q33973851-DF5DE606-4503-4AF0-8E4C-45DFD51F828BQ34143160-CF549F4D-8AA6-4D5B-98A3-3ABE449FF19DQ34153529-414BC2A9-0C44-45BB-A9D6-3E827A569CAFQ35091202-F3BBCC6D-94DD-49B2-9168-A0171AF4A5D3Q35099038-482DE3CE-DBDF-4D04-850F-871F1E3C3A16Q35186048-2E3337AC-974A-4C58-918F-5082FAD938AAQ35637966-87D825FD-F897-4551-BAB3-115977728783Q36041293-3F3A48DE-AE4B-4D78-BB7F-1673B0FF3D7CQ36089063-7C796DB4-4576-4A77-99ED-E44065EE0653Q36445998-47944E24-E8CE-4EAA-9C8D-8055A3A2FED9Q36554146-9CD8248D-4B34-42C7-9497-1227FCB13D21Q36749515-C7F2D62D-724E-4549-ADC6-4D05D8BBC379Q36870924-B0792650-6497-4A0A-AE1E-5DA642BE430CQ36946394-559B40BE-25B9-4479-B61E-AD09F0607661Q37090059-4F390D9D-D2D4-467F-9B15-603731B3A6B4Q37124476-A81A4D6C-D26C-461A-9E11-3718223E174AQ37206942-645D7C0C-082D-4A07-9146-C878A7FDAC1CQ37356757-255A7CC2-1D61-43E3-8164-247388D49A51Q37373602-D7C3E837-D4FB-4799-9861-CCF6758C70A7Q37460639-D79B6F99-D035-48EE-8D43-7DF62781E557Q37485303-07A50130-49A4-479D-BBA9-958B552ECBA2Q37691042-45A6278B-9746-4779-8196-029D224ADBF0Q37782039-0FE8DA7C-6737-4824-8103-4D815D76D471Q37910891-AF251BC1-AC4E-468F-81E3-D1B6F2C4091CQ38032563-CC0C7063-B609-467D-8E80-A9E3044E04C9Q38079701-7F4CF308-98F7-4002-A1D4-908E1AE67F9EQ38089866-6F04796A-96B5-4BB5-8429-F34A83A7E6A0Q38105940-C9CC971E-F14E-4180-B690-41BF5469C910Q38123116-507FB239-9AE3-4AB5-9485-F322CEB62329Q38791752-60BA7686-F34B-4962-A7E3-BEA5171AE6DBQ38893238-3235A69B-6916-4DA4-9B5D-D62D39DD2163Q39053375-274A652F-F93C-42B4-BA91-892F9AB9CFD1Q40291328-1C9FB649-6FC0-49BB-81E4-9A1B2E431944Q40425414-68907A08-C78F-470E-8772-34B09F025F08Q40770483-A2E7CDC3-77D2-43A5-91D8-9EB1841FBEA6Q44756980-BC1E0EB9-83A3-4960-AE07-67533234B746Q46594268-2A965293-59DA-4195-9016-C8D7D735B443
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Quality of care indicators for gout management.
@ast
Quality of care indicators for gout management.
@en
type
label
Quality of care indicators for gout management.
@ast
Quality of care indicators for gout management.
@en
prefLabel
Quality of care indicators for gout management.
@ast
Quality of care indicators for gout management.
@en
P2093
P2860
P356
P1476
Quality of care indicators for gout management.
@en
P2093
Catherine H MacLean
Fausto Patino
Jason Olivieri
John T Farrar
Kenneth G Saag
Ted R Mikuls
Warren B Bilker
P2860
P304
P356
10.1002/ART.20102
P577
2004-03-01T00:00:00Z